CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2018 Pan Pacific Lymphoma Conference
Oncology Conference Multimedia
View more videos >>
Dr. Lonial Discusses Emerging Agents in Relapsed/Refractory Myeloma
Dr. Smith Discusses Brentuximab Vedotin in CTCL
Dr. Roschewski Discusses DA-EPOCH-R in Burkitt Lymphoma
Oncology Conference Articles
Ansell Discusses Combination Potential in Hodgkin Lymphoma
Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.
Lonial Lays Out Optimal Sequence Strategies for Relapsed/Refractory Myeloma
Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.
US Versus European Opinions on Upfront Therapy in Hodgkin Lymphoma
United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.
Bleomycin Linked to High Rate of Pulmonary Disorders among Patients with Hodgkin Lymphoma
A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.
Treatment Options for CD30-Positive PTCL Subtypes
Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.
The Future of Myeloma Induction May Be Quadruplets
Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.
Navigating the Toxicities of Novel-Novel Combinations in Lymphoma
Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.
Kahl Shares Antibody-Drug Conjugate Updates in Lymphoma
With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.
Key Characteristics Emerging for CAR T Cell Success
An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.
FDA Approval in CTCL, Breakthrough Therapy Designation in CRC, and More
FDA Approves Lenvatinib for Frontline HCC
CDK4/6 Inhibitors, Other Treatment Advances Show Hope for Patients With Breast Cancer
Immunotherapy Data Lead Lung Cancer Landscape Following ASCO 2018
Climbing to New Heights: James Berenson, MD, and the Institute for Myeloma and Bone Cancer Research
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.